Zahra Toossi1, Mianda Wu, Shigou Liu, Christina S Hirsch, Jessica Walrath, Marieke van Ham, Richard F Silver. 1. aDivision of Infectious Diseases bDivision of Pulmonary, Critical Care and Sleep Medicine, Case Western Reserve University School of Medicine cLouis Stokes Cleveland Department of Veterans Affairs Medical Center dUniversity Hospitals Case Medical Center, Cleveland, Ohio, USA eDepartment of Immunopathology, Sanquin Research at CLB and Landsteiner Laboratory, Academic Medical Center, Amsterdam, The Netherlands.
Abstract
OBJECTIVE AND DESIGN: Predisposition to opportunistic infections by Mycobacterium tuberculosis (MTB) is a concomitant of HIV-1 infection and occurrence of tuberculosis is independent of circulating CD4(+) T-cell count in HIV-1-infected patients. Infection of mononuclear phagocytes from healthy individuals by virulent MTB is associated with expression of the antiapoptotic molecule protease inhibitor 9 (PI-9), and PI-9 contributes to successful parasitism of macrophages by MTB. Here we studied the contribution of PI-9 to successful MTB infection of monocytes from HIV-1-infected patients. METHODS: Blood monocytes obtained from HAART-treated HIV-1-infected patients (HIV+) and healthy controls were assessed for support of MTB H37Rv growth by assessment of MTB 16S ribosomal (r)RNA in cell lysates on day 1 and day 7 by real-time reverse transcription-PCR. PI-9 expression in monocyte cell lysates was assessed by ELISA and by reverse transcription-PCR. Inhibition of intracellular PI-9 was achieved by siRNA to PI-9 and compared to control constructs. RESULTS: Monocytes from HIV-infected patients supported higher MTB growth [MTB 16S rRNA (d7/d1)] as compared with monocytes from healthy controls. Both PI-9 protein and mRNA were significantly higher in monocytes from HIV-infected patients as compared with healthy controls. PI-9 protein levels prior to MTB infection correlated with MTB replication on day 7, and with plasma soluble CD14 levels. Silencing of PI-9 by transfection of monocytes from HIV-1-infected patients with PI-9-specific siRNA prior to infection improved intracellular containment of MTB. CONCLUSION: Increased intracellular PI-9 activity in mononuclear phagocytes from HIV-infected patients contributes to successful intracellular infection by virulent MTB.
OBJECTIVE AND DESIGN: Predisposition to opportunistic infections by Mycobacterium tuberculosis (MTB) is a concomitant of HIV-1 infection and occurrence of tuberculosis is independent of circulating CD4(+) T-cell count in HIV-1-infectedpatients. Infection of mononuclear phagocytes from healthy individuals by virulent MTB is associated with expression of the antiapoptotic molecule protease inhibitor 9 (PI-9), and PI-9 contributes to successful parasitism of macrophages by MTB. Here we studied the contribution of PI-9 to successful MTB infection of monocytes from HIV-1-infectedpatients. METHODS: Blood monocytes obtained from HAART-treated HIV-1-infectedpatients (HIV+) and healthy controls were assessed for support of MTBH37Rv growth by assessment of MTB 16S ribosomal (r)RNA in cell lysates on day 1 and day 7 by real-time reverse transcription-PCR. PI-9 expression in monocyte cell lysates was assessed by ELISA and by reverse transcription-PCR. Inhibition of intracellular PI-9 was achieved by siRNA to PI-9 and compared to control constructs. RESULTS: Monocytes from HIV-infectedpatients supported higher MTB growth [MTB 16S rRNA (d7/d1)] as compared with monocytes from healthy controls. Both PI-9 protein and mRNA were significantly higher in monocytes from HIV-infectedpatients as compared with healthy controls. PI-9 protein levels prior to MTB infection correlated with MTB replication on day 7, and with plasma soluble CD14 levels. Silencing of PI-9 by transfection of monocytes from HIV-1-infectedpatients with PI-9-specific siRNA prior to infection improved intracellular containment of MTB. CONCLUSION: Increased intracellular PI-9 activity in mononuclear phagocytes from HIV-infectedpatients contributes to successful intracellular infection by virulent MTB.
Authors: R R Annand; J R Dahlen; C A Sprecher; P De Dreu; D C Foster; J A Mankovich; R V Talanian; W Kisiel; D A Giegel Journal: Biochem J Date: 1999-09-15 Impact factor: 3.857
Authors: J Sun; C H Bird; V Sutton; L McDonald; P B Coughlin; T A De Jong; J A Trapani; P I Bird Journal: J Biol Chem Date: 1996-11-01 Impact factor: 5.157
Authors: Vojo Deretic; Isabelle Vergne; Jennifer Chua; Sharon Master; Sudha B Singh; Joseph A Fazio; George Kyei Journal: Cell Microbiol Date: 2004-11 Impact factor: 3.715
Authors: Henry C Mwandumba; David G Russell; Mukanthu H Nyirenda; Jennifer Anderson; Sarah A White; Malcolm E Molyneux; S Bertel Squire Journal: J Immunol Date: 2004-04-01 Impact factor: 5.422